Expression of core-glycosylated HCV envelope proteins in yeast

US7048930B2 · kind B2 · utility

Assignee

• Innogenetics N.V. · BE

Inventors

• Fons Bosman · Opwijk, BE
• Erik Depla · Laarne, BE
• Geert Deschamps · Aalter, BE
• Erwin Sablon · Mechelen, BE
• Isabelle Samson · Heule, BE
• Annie Van Broekhoven · Berchem, BE
• Joost Haelewyn · Evergem, BE

Key dates

• Filing date: Apr 24, 2002
• Grant date: May 23, 2006
• Expiry date: Jan 26, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2770/24223
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the general field of recombinant protein expression, purification of recombinant proteins, diagnosis of HCV infection, prophylactic treatment against HCV infection and to the prognosing/monitoring of the clinical efficiency of treatment of an individual with chronic hepatitis, or the prognosing/monitoring of the natural disease. In particular, the present invention relates to the use of yeast, i.e. Hansenula or Saccharomyces glycosylation minus strains, for the efficient expression of HCV envelope proteins that are core-glycosylated, purification methods for these proteins, and the use in various applications, such as the use in diagnosis, prophylaxis or therapy of HCV envelope proteins purified according to the present invention.